We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urine Sample Collection Tubes Relaunched for Microbial Diagnostics

By LabMedica International staff writers
Posted on 02 Dec 2015
Print article
The VACUETTE Urine CCM tube
The VACUETTE Urine CCM tube (Photo courtesy of Greiner Bio-One)
A next-generation urine sample collection tube contains an innovative additive that effectively stabilizes bacterial count for up to 48 hours at room temperature, enabling more reliable clinical diagnosis and research.

The medical threshold for diagnosing a urinary tract infection (UTI) is ≥105 CFU/mL. Accurate determination of bacteria count at or very near urine sampling is critical for correct diagnosis. However, rapid bacterial growth in urine samples can lead to false positive results, which would lead to patients taking antibiotics unnecessarily.

The new VACUETTE Urine CCM tube from Greiner Bio-One International GmbH (Kremsmünster, Austria) was introduced in 2014 and is now being relaunched as particularly suitable for microbiological diagnostics and research. The tube contains a highly soluble powder that quickly impedes bacterial growth upon simple thorough mixing with urine sample via only a few inversions of the tube. The sample remains stable with no need for refrigeration – up to 48 hours when stored at 20–25 °C.

Another advantage of the VACUETTE Urine CCM tube is its easy-to-open safety cap that allows for hygienic opening and working conditions – without risk of splashes as may occur with standard rubber stoppers. Plus, the tube is shatterproof and made from highly transparent PET plastic.

A large number of obligatory and optional pathogenic urogenital bacteria can be stabilized in the VACUETTE Urine CCM tube for reliable detection up to 48 hours. UTIs are most commonly caused by Escherichia coli or Staphylococcus spp. In addition to these two bacteria, internal GBO studies have verified the stabilization of Salmonella enteritidis, Candida albicans, and Enterococcus faecalis, and that even certain sensitive microorganisms, such as Streptococcus spp., are stabilized sufficiently.

Related Links:

Greiner Bio-One International GmbH


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Centromere B Assay
Centromere B Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.